BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical firm centered on growing life-changing therapies for allergic and immunologic illnesses, in the present day introduced that it’s going to current preliminary navenibart ALPHA-STAR information on the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
Raffi Tachdjian, M.D., MPH, Affiliate Scientific Professor of Medication and Pediatrics within the Division of Allergy and Scientific Immunology on the David Geffen College of Medication on the College of California, Los Angeles (UCLA), will current a poster titled ALPHA-STAR, a Part 1b/2 Scientific Trial of Single and A number of Doses of STAR-0215 in Sufferers with Hereditary Angioedema: Preliminary Security and Efficacy Outcomes. The poster can be introduced in e-poster showcase six on Thursday, September 26 at 4:20pm CEST.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical firm, and our mission is to carry life-changing therapies to sufferers and households affected by allergic and immunologic illnesses. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in medical growth for the therapy of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical growth for the therapy of atopic dermatitis. Study extra about our firm on our web site, www.astriatx.com, or comply with us on X and Instagram @AstriaTx and on Fb (NASDAQ:) and LinkedIn.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240919236987/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
[email protected]
Supply: Astria Therapeutics, Inc.
